- Faricimab rechallenge after mild intraocular inflammation may lead to occlusive retinal vasculitis and irreversible vision loss.
- Immunologic mechanisms, such as delayed hypersensitivity reactions, are implicated in the development of occlusive retinal vasculitis.
- Patients with neovascular age-related macular degeneration and diabetic macular edema were affected.
- Similar cases have been observed with other anti-VEGF agents, such as brolucizumab and pegcetacoplan.
- Caution is advised when rechallenging patients with prior intraocular inflammation from anti-VEGF agents.
Source: JAMA Ophthalmology
